Published in final edited form as:

Expert Rev Endocrinol Metab. 2008 November 1; 3(6): 715–724. doi:10.1586/17446651.3.6.715.

Biotin and biotinidase deficiency

Janos Zemleni[†],

Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68586, USA, Tel.: +1 402 472 3270, Fax: +1 402 472 1587, zemleni2@unl.edu

Yousef I Hassan, and

Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68586, USA, Tel.: +1 402 472 3286, Fax: +1 402 472 1587

Subhashinee SK Wijeratne

Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68586, USA, Tel.: +1 402 472 3286, Fax: +1 402 472 1587

Abstract

Biotin is a water-soluble vitamin that serves as an essential coenzyme for five carboxylases in mammals. Biotin-dependent carboxylases catalyze the fixation of bicarbonate in organic acids and play crucial roles in the metabolism of fatty acids, amino acids and glucose. Carboxylase activities decrease substantially in response to biotin deficiency. Biotin is also covalently attached to histones; biotinylated histones are enriched in repeat regions in the human genome and appear to play a role in transcriptional repression of genes and genome stability. Biotin deficiency may be caused by insufficient dietary uptake of biotin, drug–vitamin interactions and, perhaps, by increased biotin catabolism during pregnancy and in smokers. Biotin deficiency can also be precipitated by decreased activities of the following proteins that play critical roles in biotin homeostasis: the vitamin transporters sodium-dependent multivitamin transporter and monocarboxylate transporter 1, which mediate biotin transport in the intestine, liver and peripheral tissues, and renal reabsorption; holocarboxylase synthetase, which mediates the binding of biotin to carboxylases and histones; and biotinidase, which plays a central role in the intestinal absorption of biotin, the transport of biotin in plasma and the regulation of histone biotinylation. Symptoms of biotin deficiency include seizures, hypotonia, ataxia, dermatitis, hair loss, mental retardation, ketolactic acidosis, organic aciduria and also fetal malformations. This review focuses on the deficiencies of both biotin and biotinidase, and the medical management of such cases.

Keywords

biotin; biotinidase; carboxylases; deficiency; histones; holocarboxylase synthetase

Biotin

Biotin is an essential water-soluble vitamin and the adequate intake (AI) for adults is 30 µg/day [1]. Biotin serves as a coenzyme for acetyl-CoA carboxylases (ACC) α and ACC β , propionyl-CoA carboxylase (PCC), 3-methylcrotonyl-CoA carboxylase (MCC) and pyruvate carboxylase (PC); biotin is covalently bound to the ϵ -amino group of a specific lysine residue in carboxylases [2]. The biotin-dependent carboxylases catalyze pathways involved in fatty

[†]Author for correspondence Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, NE 68586, USA, Tel.: +1 402 472 3270, Fax: +1 402 472 1587, jzemleni2@unl.edu.

For reprint orders, please contact reprints@expert-reviews.com

acid biosynthesis, gluconeogenesis, tricarboxylic acid cycle anaplerosis and pleiotropic gene regulation, particularly for genes in carbohydrate metabolism. ACC α , the only human carboxylase to reside in the cytoplasm [2,3], catalyzes the binding of bicarbonate to acetyl-CoA, generating malonyl-CoA for fatty acid synthesis [2,3]. ACC β , PCC, MCC and PC are located in the mitochondrial matrix. ACC β participates in the regulation of fatty acid oxidation and might also serve as a reservoir for biotin [3,4]. PCC and MCC each comprise of biotin-containing α -subunits and biotin-free β -subunits [2]. PCC catalyzes essential steps in the metabolism of amino acids, cholesterol and odd-chain fatty acids [2], and MCC catalyzes an essential step in leucine metabolism. PC catalyzes an essential step in gluconeogenesis [2] and also plays important roles in lipogenesis [5,6], glucose-induced insulin release [7] and tricarboxylic acid anaplerosis [8]. Therefore, biotin homeostasis is crucial for maintaining normal body functions, in particular, in the heart muscle and brain [8,9]. Biotin homeostasis is achieved by efficient, transporter-mediated intestinal absorption and cellular transport of biotin by enzyme-mediated conjugation of biotin to carboxylases, and by an efficient recycling mechanism that minimizes the urinary excretion of biotin.

The following three proteins play major roles in the homeostasis of biotin (Figure 1): biotinidase (BTD), the sodium-dependent multivitamin transporter (SMVT) and holocarboxylase synthetase (HCS). Dietary biotin exists in free and protein-bound forms [10]. Gastrointestinal proteases and peptidases digest biotin-containing proteins to release biocytin (biotinyl- ϵ -lysine) and biotin-containing peptides [11]. BTD is secreted in pancreatic fluids and plays a critical role in releasing free biotin from biocytin and biotinylated peptides prior to absorption. Intestinal BTD may also be derived from the intestinal flora, intestinal secretions and brushborder membranes [11,12].

The SMVT is responsible for intestinal absorption of free biotin, renal reabsorption and transport across cell membranes in liver and peripheral tissues [13–15]. In lymphoid cells, the monocarboxylate transporter 1 might also contribute to biotin uptake [16]. BTD is secreted in large quantities into blood plasma and participates in the transport of biotin to peripheral tissues [11].

The attachment of biotin to lysine residues in carboxylases and histones (see later) is catalyzed by HCS [17–19]. Biotin-dependent carboxylases have half-lives of 1–8 days [20–25]. Degradation of holocarboxylases leads to the release of biocytin and biotinylated peptides. BTD catalyzes the release of free biotin from these breakdown products for recycling in holocarboxylase synthesis. Taken together, BTD plays a fundamental role in biotin homeostasis and, therefore, is the focus of this review article.

Biotin deficiency

Mock and coworkers provided evidence that approximately half of the pregnant women in the USA are marginally biotin-deficient, despite a normal dietary biotin intake [26–28]. These claims are based on comparisons of well-known markers of biotin status in pregnant women to those in nonpregnant women (e.g., the urinary excretion of 3-hydroxyisovaleric acid and biotin) and the activity of propionyl-CoA carboxylase in lymphocytes. If there was a link between marginal biotin deficiency and fetal malformations in humans, the findings by Mock and coworkers would have important implications for health policies and intake recommendations. Currently, this link is somewhat uncertain. While animal studies have clearly demonstrated that biotin deficiency is teratogenic, the severity of deficiency in these animal studies typically exceeded what was observed in pregnant women. Notwithstanding these limitations, the teratogenic effects of biotin deficiency in animal models are striking and deserve a brief summary [29–31]. For example, hens with biotin deficiency produce eggs with higher embryonic mortality, reduced hatchability and malformations such as chronodystrophy,

perosis, micromelia and syndactyly [31]. In some strains of mice, biotin deficiency during pregnancy causes substantial increases in fetal malformations and mortality [30,31]. The most common fetal malformations in biotin-deficient rats include cleft palate, micrognathia and micromelia. Differences in teratogenic susceptibility among rodent species have been reported and corresponding differences of biotin concentrations in fetal liver were observed. This led Watanabe and coworkers to propose that differences in teratogenic susceptibility among rodent species are caused by differences in biotin transport from the mother to the fetus [32]. Evidence has been provided that biotin catabolism to bisnorbiotin is increased in pregnant women compared with nonpregnant controls [26,33]. The fetal-to-maternal concentration ratio of biotin plus metabolites is approximately 6:1, suggesting that fetal biotin accumulation might contribute to maternal biotin depletion [34]. However, Mock and coworkers reported that the activity of PCC is reduced by approximately 90% in the fetus at term in response to feeding an egg white that causes only a 50% reduction in maternal hepatic PCC activity [35]. They speculated that this finding indicates that the fetus may not really be an efficient biotin parasite, in contrast to most other micronutrients.

Biotin deficiency has also been reported in individuals who are treated with anticonvulsants [36,37]. Other potential causes of biotin deficiency are intestinal malabsorption in individuals with short bowel syndrome, long-term use of drugs such as antibiotics, certain antiseizure medications and lipoic acid, excessive alcohol consumption and continuous consumption of raw egg white [38–43]. Raw egg white contains the protein avidin, which binds biotin tightly, rendering it unavailable for absorption [38,44]. Recent studies show that smoking accelerates biotin catabolism, especially in women, resulting in marginal biotin deficiency [45]. Biotin-deficient human fibroblasts undergo senescence earlier than their biotin-sufficient controls [46]. These biotin-deficient cells selectively lost mitochondrial complex IV that was associated with decreased heme synthesis. Moreover, biotin-deficient cells exhibited an increased susceptibility to oxidative damage in response to stress. Importantly, biotin deficiency has been reported in severely malnourished children [47], creating a global public-health problem [48].

BTD deficiency

Biotin deficiency may also be caused by a deficiency of the three proteins involved in biotin homeostasis: HCS, BTD and SMVT [18,49–53]. This review will not discuss SMVT and HCS, only BTD, because of its central role in biotin recycling and transport, as discussed previously. BTD deficiency can result from gene mutations, including deletions, insertions, cryptic splice site formation, single nucleotide insertion and deletion, and point mutations [54]. Mutations of the *BTD* gene have been well characterized at the molecular level [54–57] and are discussed later.

Deficiency of BTD leads to failure in releasing biotin from dietary proteins, thereby decreasing bioavailability. In addition, the urinary excretion of biotin might increase due to increased renal filtration of free biotin (lack of the biotin transport protein BTD), and impaired recycling of biotin from breakdown products of biotinylated carboxylases, such as biocytin [58–60]. Impaired serum BTD activity, together with increased biotin requirements, have also been reported in patients suffering from chronic liver diseases, such as cirrhosis [61]. Clinical and biochemical features in patients with BTD deficiency are similar to those of biotin and HCS deficiency, but not limited to those described for biotin deficiency [62,63], suggesting the existence of additional unknown activities of BTD. These BTD deficiency clinical features include hearing loss and optic atrophy in addition to the common biotin deficiency symptoms, such as seizures, hypotonia, ataxia, dermatitis, hair loss, mental retardation, ketolactic acidosis and organic aciduria [59,63–67].

Typically, findings of BTD deficiency appear at age 1 week to more than 1 year [62]. Profound BTD deficiency is characterized by less than 10% of normal serum BTD activity, whereas patients with partial deficiency possess 10–30% of normal BTD activity [68]. The estimated incidence of profound BTD deficiency is one in 112,271 and the incidence of partial BTD deficiency is one in 129,282 [68]. The combined incidence of profound and partial deficiency is one in 60,089 live births; an estimated one in 123 individuals is heterozygous for the disorder [68]. Most of the children in whom BTD deficiency has been diagnosed are Caucasian [62]. BTD-deficient patients are typically treated with lifelong daily doses of biotin 5–20 mg to compensate for decreased bioavailability from food sources and increased urinary losses [62, 68].

Failure to diagnose and treat BTD deficiency at an early stage may cause irreversible neurological damage, leading to developmental delay and autistic behavior [51,69,70]. This could be attributed to an increased vulnerability of the brain to biotin deficiency. Symptomatic patients improve rapidly if biotin therapy is initiated early; hence the prognosis of BTD deficiency is favored by early institution of biotin therapy during infancy or childhood. Biotin therapy must be continued throughout life [62,70].

Pathogenesis of BTD, HCS and biotin deficiency are similar, and multiple carboxylase deficiency is characterized by low activities of ACC, MCC, PC and PCC. BTD deficiency can be unambiguously diagnosed by using a fairly easy colorimetric assay for BTD activity in cultured amniotic fluid cells or neonatal blood samples [62]. BTD activity is measured by quantitating the release of *p*-aminobenzoic acid from *N*-biotinyl-*p*-aminobenzoate [71]. The mean ($\pm$ standard deviation [SD]) normal activity of BTD is 5.8 ± 0.9 nmol *p*-aminobenzoate liberated $\text{min}^{-1} \cdot \text{ml}^{-1}$ serum [71].

BTD gene

Biotinidase belongs to the nitrilase superfamily of enzymes, which consists of 12 families of amidases, *N*-acyltransferases and nitrilases [72]. Some members of the nitrilase superfamily (vanins-1, -2 and -3) share significant sequence similarities with BTD [73]; it is unknown whether vanins use histones as acceptor molecules in transferase reactions (see later). Human *BTD* gene has been cloned, sequenced and characterized [74]. The gene localizes to human chromosome 3p25. The structure of the human *BTD* gene has been determined [75]; the 5'-flanking region of exon 1 contains a CCAAT element, three initiator sequences, an octamer sequence, three methylation consensus sites, two GC boxes and one hepatocyte nuclear factor (HNF)-5 site, but has no TATA element. The organization of the *BTD* gene reveals features of a CpG island and resembles a housekeeping gene promoter in region -600 to +400 relative to the transcription start site. The human *BTD* gene contains four exons, which span at least 44 kb and encode a protein of 543 amino acids [76]. The four exons have been designated A-125-44, B₄₅₋₃₀₉, C₃₁₀₋₄₅₉ and D₄₆₀₋₁₉₆₁. The mature enzyme is encoded by exons B through D. The coding region of BTD has two in-frame start codons, both of which might initiate translation. Recently, three alternatively spliced variants of BTD have been identified in multiple human tissues: alternative splicing occurs in exon A (exon 1) and the three variants were designated 1a, 1b and 1c [76,77].

The cellular distribution of BTD is controversial. While the existence of BTD activity in microsomes and mitochondria is accepted universally [78–80], the presence of BTD in nuclei is less certain. Pispa proposed that 26% of the cellular BTD activity is located in the nuclear fraction [80], which was confirmed by subsequent immunocytochemistry studies [81]. No nuclear BTD was detected by Stanley *et al.* [76]. Alternative splicing of BTD might play a role in regulating its subcellular localization and tissue specificity [76]. For example, the 1c variant can only be detected in the testes [76]. Mature BTD (85 kDa) has been detected in microsomes

and lysosomes, whereas a 48-kDa BTD variant was detected in mitochondria [76]. The 85-kDa protein possesses full biotinyl-hydrolase and transferase abilities, whereas the 48-kDa variant lacks those activities [76]. It cannot formally be excluded that the 48-kDa protein is an artifact produced by protein breakdown during sample preparation.

The structure of the BTD protein has not yet been characterized in great detail, primarily due to the absence of crystallography data. The expression and purification of bioactive BTD has proven to be difficult [82]. This obstacle has been partially by-passed by using *in silico* modeling to predict the 3D structure of BTD [82]. This model is based on crystallography data from prokaryotic nitrilase and amidase domains. The BTD model predicts a protein with two major domains. Using sequence comparisons among mammals and *Drosophila*, a 62-amino acid conserved region was identified that probably harbors the active site of BTD [83]. Highly conserved glutamate, lysine and cysteine residues (Glu112, Lysine212 and Cys245) were also identified [82]. Using the *in silico* model, Pindolia *et al.* characterized 45 missense mutations known to affect BTD activity [82]. Finally, the model predicts the existence of multiple disulfide bonds needed for enzyme stability and correct folding in addition to six glycosylation sites located on the surface of BTD that might also be involved in the enzyme function, secretion into the extracellular space and cellular localization. These model predictions are consistent with previous observations in disulfide bond formation and glycosylation of BTD [76]. The controversial roles of BTD in the biotinylation and debiotinylation of histones are discussed later.

More than 110 BTD mutations have been reported that decrease BTD activity (Online Mendelian Inheritance in Man [OMIM] accession #609019), leading to multiple carboxylase deficiency as described previously [201]. This field of research has been pioneered by Wolf and coworkers [54,77,84–86]. Both early-onset (neonatal) and late-onset (juvenile) forms of BTD deficiency have been reported [87]. It has been speculated that the early-onset forms of BTD deficiency (multiple carboxylase deficiency) might be caused by mutations in the *BTD* gene, whereas the late-onset forms might be caused by decreased secretion of BTD into the intestinal lumen [88].

Research by Wolf and coworkers identified a number of mutations in the *BTD* gene that account for most of the observed cases of BTD deficiency. For example, 50% of symptomatic children have a 7-bp deletion coupled with a 3-bp insertion in at least one of their alleles of the *BTD* gene or a substitution that corresponds to a R538C change [77]. Other aberrations include a deletion/insertion mutation in exon D_{460–1961} that causes a frame shift and premature termination and the translation of a truncated protein [77]. Recently, Wolf *et al.* reported 17 novel mutations that cause profound BTD deficiency [85]. Six of the reported mutations are due to deletions, whereas the remaining 11 mutations are missense mutations located throughout the gene, and encode amino acids that are conserved in mammals. Hymes *et al.* reported 61 mutations that take place in three of the four exons of the *BTD* gene and one mutation in an intron associated with profound BTD deficiency [54]. Finally, Muhl *et al.* analyzed samples from 21 patients with profound BTD deficiency and 13 patients with partial BTD deficiency [89]. Of the cases of partial BTD deficiency, the D444H mutation was the dominant mutation, accounting for 92% of cases.

Histone biotinylation

Chromatin & gene regulation

Chromatin comprises DNA and DNA-binding proteins (i.e., histones and nonhistone proteins). Histones play a predominant role in the folding of DNA into chromatin [90]. Five major classes of histones have been identified in mammals: H1, H2A, H2B, H3 and H4. Histones consist of a globular domain and a more flexible amino terminus (histone ‘tail’). DNA and histones form

repetitive nucleoprotein units, the nucleosomes [90]. Each nucleosome (nucleosomal core particle) consists of 147 bps of DNA wrapped around an octamer of core histones (one H3–H3–H4–H4 tetramer and two H2A–H2B dimers). One molecule of histone H1 is positioned on top of each nucleosome, binding to the linker DNA region between the histone beads.

The amino terminal tail of histones protrudes from the nucleosomal surface; covalent modifications of this tail affect the structure of chromatin and form the basis for gene regulation [91–96]. Amino acid residues in histone tails are modified by covalent acetylation [97–99], methylation [90], phosphorylation [90], ubiquitination [90] and poly (ADP-ribosylation) (Figure 2) [100–102]. The various modifications of histones have distinct functions. For example, trimethylation of K4 in histone H3 is associated with transcriptional activation of surrounding DNA, whereas dimethylation of K9 is associated with transcriptional silencing [95,103]. Covalent modifications of histones are reversible [95].

Histone biotinylation

The classical role of biotin is to serve as a covalently bound coenzyme for five carboxylases (see previously); biotinylation of carboxylases is catalyzed by HCS [2]. Recently, we provided evidence that biotin is also linked to histones (DNA-binding proteins) via an amide bond [104]. In previous studies, we identified eleven distinct biotinylation sites in histones H2A, H3 and H4 (Figure 2) and generated site-specific antibodies to these biotinylated histones [105–108]. Bailey *et al.* proposed that streptavidin (a classical probe for biotin) binds to histones independently of biotin and cautioned against the use of streptavidin when probing biotinylated histones [109]. These studies make a case for using biotinylation site-specific antibodies in chromatin studies.

Functions of histone biotinylation in chromatin remodeling are emerging. For example, biotinylation of K12 in histone H4 plays roles in gene repression, DNA repair, heterochromatin structures and repression of transposons to mediate genomic stability and minimize cancer risk in human cells and *Drosophila melanogaster* [19,110–113]. Importantly, biotinylation of histones depends on biotin supply [114,115] and, therefore, might be decreased in BTB-deficient patients where biotin recycling is impaired [19,111]. It is unknown what percentage of lysine residues in histones is biotinylated. Studies in telomeric repeats provided evidence that approximately one out of three molecules of histone H4 is biotinylated at K12 in this region (Wijeratne SSK, Unpublished Observation). Less than 1% of total cellular biotin localizes to the cell nucleus [104].

Initially, it was proposed that BTB mediates biotinylation of histones. Hymes *et al.* have proposed a reaction mechanism by which cleavage of biocytin (biotin- ϵ -lysine) by BTB leads to the formation of a biotinyl-thioester intermediate (cysteine-bound biotin) at or near the active site of BTB [59,116]. In a next step, the biotinyl moiety is transferred from the thioester to the ϵ -amino group of lysine in histones. The substrate (biocytin) for biotinylation of histones is generated in the breakdown of biotin-dependent carboxylases, which contain biotin linked to the ϵ -amino group of a lysine moiety [62,80].

Recently, Narang *et al.* provided evidence that HCS can also biotinylate histones [18]. Notwithstanding the ability of BTB to catalyze biotinylation of histones, studies by Camporeale *et al.* suggest that HCS is more important than BTB for biotinylation of histones [19]. Importantly, knockdown of HCS and BTB decrease histone biotinylation, cause abnormal gene expression patterns and phenotypes such as decreased life span and heat resistance in *D. melanogaster* [19]. Effects of BTB knockdown can probably be attributed to a secondary biotin deficiency due to impaired biotin recycling.

Debiotinylation of histones

Biotinylation of histones is a reversible modification, but the mechanisms mediating debiotinylation of histones are largely unknown. Recent studies suggest that BTD may catalyze both biotinylation and debiotinylation of histones [117]. Variables such as the microenvironment in chromatin, post-translational modifications and alternate splicing of BTD might determine whether BTD acts as biotinyl histone transferase or histone debiotinylase. This assumption is based on the following lines of reasoning. First, the availability of substrate might favor either biotinylation or debiotinylation of histones. For example, locally high concentrations of biocytin might increase the rate of histone biotinylation in confined regions of chromatin. Note that the pH is unlikely to affect the biotinylation equilibrium, given that the pH optimum is similar (pH 8) for both the biotinylating activity [116] and the debiotinylating activity of BTD [117]. Second, proteins may interact with BTD at the chromatin level, favoring either biotinylation or debiotinylation of histones. Third, three alternatively spliced variants of BTD have been identified [76]. Theoretically, these variants may have unique functions in histone metabolism. Fourth, some variants of BTD are modified post-translationally by glycosylation [74,76], potentially affecting enzymatic activity. An assay for analysis of histone debiotinylases is available [81].

Synthetic BTD inhibitors & analytical tools

BTD inhibitors

Classical studies of biotin metabolism proposed using biotin, di-isopropylfluorophosphate and thiol reagents, such as *p*-chloromercuribenzoate, as inhibitors of BTD *in vitro* [80]. By today's standards, these compounds are of limited use for the following two reasons. First, di-isopropylfluorophosphate and *p*-chloromercuribenzoate are general inhibitors of enzymes as opposed to being specific inhibitors of BTD. Second, simultaneous inhibition of BTD in both cytoplasm and the nucleus make it impossible to link potential effects of low BTD activity to altered histone debiotinylation in the nucleus as opposed to impaired biotin recycling in the cytoplasm. Recently, Kobza *et al.* identified synthetic biotin analogs that specifically inhibit BTD [107]. The following compounds inhibited BTD activity by 26–80% if used at a concentration of 1 mmol/l: biotinyl anilide, biotinyl allylamide, biotinyl *N*-methylanilide, biotinyl-methyl 4-(amidomethyl) benzoate, biotinyl 2-amido-pyridine, biotinyl 4-amidophenylboronic acid and biotinyl benzylamide. Biotinyl-methyl 4-(amidomethyl) benzoate was the most effective compound of all the inhibitors tested. Enzyme kinetics studies were consistent with the hypothesis that these compounds acted by competitive inhibition of BTD. Biotinyl-methyl 4-(amidomethyl) benzoate did not affect biotin transport in human cells, suggesting specificity in regard to biotin-related processes. The development of these inhibitors is an important first step towards the generation of BTD-specific and cell compartment-specific inhibitors. Second-generation inhibitors will need to be designed to prevent hydrolytic cleavage of amide bonds in biotin analogs and to target inhibitors to specific cellular compartments (e.g., nuclei).

Analytical tools

Kobza *et al.* adopted an existing colorimetric BTD assay for use in a novel 96-well plate format to permit high-throughput screening of potential BTD inhibitors [107]. Antibodies to BTD are available [105].

Expert commentary

The importance of biotin for human health has been under-appreciated for many years. Health professionals thought that the role of biotin in human well-being was limited to that as a coenzyme for carboxylases and that biotin deficiency was fairly rare in free-living humans.

This view has changed considerably over the past few years. Evidence has been provided that marginal biotin deficiency might be more common than widely believed, particularly in certain subgroups of the general population, such as pregnant women, patients treated with certain drugs and severely malnourished children. The significance of biotin deficiency in humans has been underlined by observations that biotin deficiency is teratogenic in some animal species. A link between marginal biotin deficiency in pregnant women and the incidence of birth defects has yet to be established. Similarly, it will be important to validate cut-off points to define biotin deficiency in pregnant women. Importantly, it is now clear that biotin plays a role in chromatin structure, mediated by its binding to distinct lysine residues in several classes of histones. Abnormally low biotinylation of histones appears to impair gene repression and repression of transposable elements, thereby decreasing genome stability. Here, too, there is plenty of opportunity for future research with a potentially great relevance for human health. For example, it is currently unknown how enzymes that mediate biotinylation of histones are being targeted to distinct regions in human chromatin. Similarly, the mechanisms of gene repression by histone biotinylation have not yet been established. Finally, while it has been proposed that BTD acts as a histone debiotinylase, no unambiguous evidence for such a role has yet been provided. Health professionals are encouraged to keep up-to-date with the exciting new findings made in the biotin field because of the significance of this vitamin for human health. Similarly, researchers are encouraged to engage in biotin research because of the great opportunities offered by the recent developments in this field.

Five-year view

Undoubtedly, a bulk of new information will emerge with regard to structures, functions and mutations of HCS and BTD owing to the importance of these enzymes in biotin homeostasis and chromatin structure. Structural analyses are already underway in a few select laboratories. Identification of novel histone biotinylation sites and characterization of their biological functions is just a matter of time. While the mechanism of action of histone biotinylation in mediating gene regulation might remain obscure for a few more years, one might speculate that RNAi might play an important role. Future research will probably characterize links between histone biotinylation and DNA methylation and, perhaps, other epigenetic phenomena. The roles of biotin in chromatin structure will also probably offer explanations for why biotin deficiency causes fetal malformations. In that context, it is anticipated that biotin requirements and homeostasis in pregnant women and their fetuses will be much clearer defined during the course of the next 5 years.

Key Issues

- Biotin is a water-soluble vitamin that serves as a coenzyme for five carboxylases in humans. Carboxylases play essential roles in macronutrient metabolism.
- Biotin is also covalently attached to histones. Biotinylation of histones plays a role in gene repression and repression of transposable elements, thereby maintaining genome stability.
- Biotin homeostasis is maintained by dietary intake, the biotin transporters monocarboxylate transporter 1 and sodium-dependent multivitamin transporter, the biotin protein ligase holocarboxylase synthetase and the biotin peptidyl hydrolase biotinidase (BTD).
- Evidence has been provided that approximately 50% of pregnant women are marginally biotin deficient and that severe biotin deficiency is teratogenic in some animals. Biotin status is impaired by interactions with some drugs and in severely malnourished children.

- BTD plays multiple roles in biotin metabolism (i.e., intestinal release of free biotin and plasma transport) and the recycling of biotin from breakdown products of biotinylated carboxylases.
- The exact role of BTD in the regulation of histone biotinylation is uncertain.
- More than 110 mutations have been identified in the *BTD* gene.

Acknowledgments

Financial & competing interests disclosure

A contribution of the University of Nebraska Agricultural Research Division, supported in part by funds provided through the Hatch Act. Additional support was provided by NIH grants DK063945, DK077816 and ES015206, USDA grant 2006–35200–17138, and by NSF EPSCoR grant EPS-0701892. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

1. National Research Council. Food and Nutrition Board, Institute of Medicine. National Academy Press; Washington, DC, USA: 1998. *Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B₆, Folate, Vitamin B₁₂, Pantothenic Acid, Biotin, and Choline*.
2. Camporeale, G.; Zempleni, J. Biotin. In: Bowman, BA.; Russell, RM., editors. Present Knowledge in Nutrition. International Life Sciences Institute; Washington, DC, USA: 2006. p. 314–326.
3. Kim K-H, McCormick DB, Bier DM, Goodridge AG. Regulation of mammalian acetyl-coenzyme A carboxylase. *Ann Rev Nutr* 1997;17:77–99. [PubMed: 9240920]
4. Shriver BJ, Roman-Shriver C, Allred JB. Depletion and repletion of biotinyl enzymes in liver of biotin-deficient rats: evidence of a biotin storage system. *J Nutr* 1993;123:1140–1149. [PubMed: 8099368]
5. Freytag SO, Utter MF. Induction of pyruvate carboxylase apoenzyme and holoenzyme in 3T3–L1 cells during differentiation. *Proc Natl Acad Sci USA* 1980;77(3):1321–1325. [PubMed: 6929488]
6. Jitrapakdee S, Slawik M, Medina-Gomez G, et al. The peroxisome proliferator-activated receptor- γ regulates murine pyruvate carboxylase gene expression in vivo and in vitro. *J Biol Chem* 2005;280(29):27466–27476. [PubMed: 15917242]
7. MacDonald MJ. Feasibility of a mitochondrial pyruvate malate shuttle in pancreatic islets. Further implication of cytosolic NADPH in insulin secretion. *J Biol Chem* 1995;270(34):20051–20058. [PubMed: 7650022]
8. Garrett, RH.; Grisham, CM. Biochemistry. Saunders College Publishing; TX, USA: 1995.
9. Ozand PT, Gascon GG, Essa MA, et al. Biotin-responsive basal ganglia disease: a novel entity. *Brain* 1998;121(Pt 7):1267–1279. [PubMed: 9679779]
10. Said HM, Thuy LP, Sweetman L, Schatzman B. Transport of the biotin dietary derivative biocytin (N-biotinyl-L-lysine) in rat small intestine. *Gastroenterology* 1993;104:75–80. [PubMed: 8419264]
11. Wolf B, Grier RE, McVoy JRS, Heard GS. Biotinidase deficiency: a novel vitamin recycling defect. *J Inher Metab Dis* 1985;8(Suppl 1):53–58. [PubMed: 3930841]
12. Bowman BB, Rosenberg I. Biotin absorption by distal rat intestine. *J Nutr* 1987;117:2121–2126. [PubMed: 3694289]
13. Said HM. Cellular uptake of biotin: mechanisms and regulation. *J Nutr* 1999;129(2 Suppl):490S–493S. [PubMed: 10064315]
14. Said HM, Ortiz A, McCloud E, et al. Biotin uptake by human colonic epithelial NCM460 cells: a carrier-mediated process shared with pantothenic acid. *Am J Physiol* 1998;275:C1365–C1371. [PubMed: 9814986]
15. Said HM. Recent advances in carrier-mediated intestinal absorption of water-soluble vitamins. *Annu Rev Physiol* 2004;66:419–446. [PubMed: 14977409]

16. Daberkow RL, White BR, Cederberg RA, Griffin JB, Zempleni J. Monocarboxylate transporter 1 mediates biotin uptake in human peripheral blood mononuclear cells. *J Nutr* 2003;133:2703–2706. [PubMed: 12949353]
17. Dakshinamurti, K.; Chauhan, J. Biotin-binding proteins. In: Dakshinamurti, K., editor. *Vitamin Receptors: Vitamins as Ligands in Cell Communication*. Cambridge University Press; Cambridge, UK: 1994. p. 200–249.
18. Narang MA, Dumas R, Ayer LM, Gravel RA. Reduced histone biotinylation in multiple carboxylase deficiency patients: a nuclear role for holocarboxylase synthetase. *Hum Mol Genet* 2004;13:15–23. [PubMed: 14613969]
19. Camporeale G, Giordano E, Rendina R, Zempleni J, Eissenberg JC. *Drosophila* holocarboxylase synthetase is a chromosomal protein required for normal histone biotinylation, gene transcription patterns, lifespan and heat tolerance. *J Nutr* 2006;136(11):2735–2742. [PubMed: 17056793]
20. Freytag SO, Utter MF. Regulation of the synthesis and degradation of pyruvate carboxylase in 3T3–L1 cells. *J Biol Chem* 1983;258(10):6307–6312. [PubMed: 6343373]
21. Weinberg MD, Utter MF. Effect of thyroid hormone on the turnover of rat liver pyruvate carboxylase and pyruvate dehydrogenase. *J Biol Chem* 1979;254:9492–9499. [PubMed: 489548]
22. Weinberg MD, Utter MF. Effect of streptozotocin-induced diabetes mellitus on the turnover of rat liver pyruvate carboxylase and pyruvate dehydrogenase. *Biochem J* 1980;188:601–608. [PubMed: 7470023]
23. Majerus P, Kilburn E. Acetyl coenzyme A carboxylase. The roles of synthesis and degradation in regulation of enzyme levels in rat liver. *J Biol Chem* 1969;244:6254–6262. [PubMed: 4981792]
24. Nakanishi S, Numa S. Purification of rat liver acetyl coenzyme A carboxylase and immunochemical studies on its synthesis and degradation. *Eur J Biochem* 1970;16:161–173. [PubMed: 4989552]
25. Rodriguez-Fuentes N, Lopez-Rosas I, Roman-Cisneros G, Velazquez-Arellano A. Biotin deficiency affects both synthesis and degradation of pyruvate carboxylase in rat primary hepatocyte cultures. *Mol Genet Metab* 2007;92(3):222–228. [PubMed: 17720579]
26. Mock DM, Stadler DD. Conflicting indicators of biotin status from a cross-sectional study of normal pregnancy. *J Am Coll Nutr* 1997;16:252–257. [PubMed: 9176832]
27. Mock DM, Quirk JG, Mock NI. Marginal biotin deficiency during normal pregnancy. *Am J Clin Nutr* 2002;75(2):295–299. [PubMed: 11815321]
28. Stratton SL, Bogusiewicz A, Mock MM, et al. Lymphocyte propionyl-CoA carboxylase and its activation by biotin are sensitive indicators of marginal biotin deficiency in humans. *Am J Clin Nutr* 2006;84(2):384–388. [PubMed: 16895887]
29. Mock DM. Marginal biotin deficiency is teratogenic in mice and perhaps humans: a review of biotin deficiency during human pregnancy and effects of biotin deficiency on gene expression and enzyme activities in mouse dam and fetus. *J Nutr Biochem* 2005;16(7):435–437. [PubMed: 15992686]
30. Mock DM, Mock NI, Stewart CW, LaBorde JB, Hansen DK. Marginal biotin deficiency is teratogenic in ICR mice. *J Nutr* 2003;133:2519–2525. [PubMed: 12888630]
31. Zempleni J, Mock DM. Marginal biotin deficiency is teratogenic. *Proc Soc Exp Biol Med* 2000;223(1):14–21. [PubMed: 10632957]
32. Watanabe T, Endo A. Species and strain differences in teratogenic effects of biotin deficiency in rodents. *J Nutr* 1989;119:255–261. [PubMed: 2918398]
33. Mock DM, Stadler D, Stratton S, Mock NI. Biotin status assessed longitudinally in pregnant women. *J Nutr* 1997;127(5):710–716. [PubMed: 9164991]
34. Mantagos S, Malamitsi-Puchner A, Antsaklis A, et al. Biotin plasma levels of the human fetus. *Biol Neonate* 1998;74:72–74. [PubMed: 9657671]
35. Sealey WM, Stratton SL, Mock DM, Hansen DK. Marginal maternal biotin deficiency in CD-1 mice reduces fetal mass of biotin-dependent carboxylases. *J Nutr* 2005;135(5):973–977. [PubMed: 15867267]
36. Mock DM. Biotin status: which are valid indicators and how do we know? *J Nutr* 1999;129(2 Suppl): 498S–503S. [PubMed: 10064317]
37. Schulpis KH, Karikas GA, Tjamouranis J, Regoutas S, Tsakiris S. Low serum biotinidase activity in children with valproic acid monotherapy. *Epilepsia* 2001;42(10):1359–1362. [PubMed: 11737173]

38. Mock DM, Henrich-Shell CL, Carnell N, Stumbo P, Mock NI. 3-hydroxypropionic acid and methylcitric acid are not reliable indicators of marginal biotin deficiency in humans. *J Nutr* 2004;134(2):317–320. [PubMed: 14747666]
39. Mock DM, Dyken ME. Biotin catabolism is accelerated in adults receiving long-term therapy with anticonvulsants. *Neurology* 1997;49(5):1444–1447. [PubMed: 9371938]
40. Mock DM, Dyken ME. Biotin deficiency results from long-term therapy with anticonvulsants. *Gastroenterology* 1995;108(4):A740.
41. Khalidi N, Wesley JR, Thoene JG, Whitehouse WM Jr, Baker WL. Biotin deficiency in a patient with short bowel syndrome during home parenteral nutrition. *JPEN J Parenter Enteral Nutr* 1984;8:311–314. [PubMed: 6429370]
42. Zempleni J, Trusty TA, Mock DM. Lipoic acid reduces the activities of biotin-dependent carboxylases in rat liver. *J Nutr* 1997;127(9):1776–1781. [PubMed: 9278559]
43. Anagnostouli M, Livaniou E, Nyalala JO, et al. Cerebrospinal fluid levels of biotin in various neurological disorders. *Acta Neurol Scand* 1999;99(6):387–392. [PubMed: 10577274]
44. Green NM. Avidin. *Adv Protein Chem* 1975;29:85–133. [PubMed: 237414]
45. Sealey WM, Teague AM, Stratton SL, Mock DM. Smoking accelerates biotin catabolism in women. *Am J Clin Nutr* 2004;80(4):932–935. [PubMed: 15447901]
46. Atamna H, Newberry J, Erlitzki R, Schultz CS, Ames BN. Biotin deficiency inhibits heme synthesis and impairs mitochondria in human lung fibroblasts. *J Nutr* 2007;137(1):25–30. [PubMed: 17182796]
47. Velazquez A, Martin-del-Campo C, Baez A, et al. Biotin deficiency in protein-energy malnutrition. *Eur J Clin Nutr* 1988;43:169–173. [PubMed: 2499449]
48. Teran-Garcia M, Ibarra I, Velazquez A. Urinary organic acids in infant malnutrition. *Pediatr Res* 1998;44(3):386–391. [PubMed: 9727718]
49. Burri BJ, Sweetman L, Nyhan WL. Mutant holocarboxylase synthetase: evidence for the enzyme defect in early infantile biotin-responsive multiple carboxylase deficiency. *J Clin Invest* 1981;68(6):1491–1495. [PubMed: 6798072]
50. Burri BJ, Sweetman L, Nyhan WL. Heterogeneity of holocarboxylase synthetase in patients with biotin-responsive multiple carboxylase deficiency. *Am J Hum Genet* 1985;37(2):326–337. [PubMed: 3920902]
51. Baumgartner ER, Suormala T. Multiple carboxylase deficiency: inherited and acquired disorders of biotin metabolism. *Int J Vitam Nutr Res* 1997;67(5):377–384. [PubMed: 9350481]
52. Wolf B, Raetz H. The measurement of propionyl-CoA carboxylase and pyruvate carboxylase activity in hair roots: its use in the diagnosis of inherited biotin-dependent enzyme deficiencies. *Clinica Chim Acta* 1983;130:25–30.
53. Mardach R, Zempleni J, Wolf B, et al. Biotin dependency due to a defect in biotin transport. *J Clin Invest* 2002;109:1617–1623. [PubMed: 12070309]
54. Hymes J, Stanley CM, Wolf B. Mutations in BTB causing biotinidase deficiency. *Hum Mutat* 2001;18(5):375–381. [PubMed: 11668630]
55. Moslinger D, Muhl A, Suormala T, Baumgartner R, Stockler-Ipsiroglu S. Molecular characterisation and neuropsychological outcome of 21 patients with profound biotinidase deficiency detected by newborn screening and family studies. *Eur J Pediatr* 2003;162(Suppl 1):S46–S49. [PubMed: 14628140]
56. Laszlo A, Schuler EA, Sallay E, et al. Neonatal screening for biotinidase deficiency in Hungary: clinical, biochemical and molecular studies. *J Inher Metab Dis* 2003;26(7):693–698. [PubMed: 14707518]
57. Neto EC, Schulte J, Rubim R, et al. Newborn screening for biotinidase deficiency in Brazil: biochemical and molecular characterizations. *Braz J Med Biol Res* 2004;37(3):295–299. [PubMed: 15060693]
58. Mock DM. Biotin. In: Rucker RB, Zempleni J, Suttie JW, McCormick DB, editors. *Handbook of Vitamins*. Taylor and Francis, Inc; FL, USA: 2006.
59. Hymes J, Wolf B. Human biotinidase isn't just for recycling biotin. *J Nutr* 1999;129(2 Suppl):485S–489S. [PubMed: 10064314]

60. Suormala T, Baumgartner ER, Bausch J, Holick W, Wick H. Quantitative determination of biocytin in urine of patients with biotinidase deficiency using high-performance liquid chromatography (HPLC). *Clinica Chim Acta* 1988;177:253–270.
61. Pabuccuoglu A, Aydogdu S, Bas M. Serum biotinidase activity in children with chronic liver disease and its clinical significance. *J Pediatr Gastroenterol Nutr* 2002;34(1):59–62. [PubMed: 11753166]
62. Wolf B.; Heard, GS. Biotinidase deficiency. In: Barness, L.; Oski, F., editors. *Advances in Pediatrics*. Medical Book Publishers; IL, USA: 1991. p. 1-21.
63. Wolf, B. Disorders of biotin metabolism. In: Scriver, CR.; Beaudet, AL.; Sly, WS.; Valle, D., editors. *The Metabolic and Molecular Basis of Inherited Disease*. McGraw-Hill Inc; New York, NY, USA: 1995. p. 3151-3177.
64. Suzuki Y, Yang X, Aoki Y, Kure S, Matsubara Y. Mutations in the holocarboxylase synthetase gene HLCs. *Hum Mutat* 2005;26(4):285–290. [PubMed: 16134170]
65. Gibson KM, Bennett MJ, Nyhan WL, Mize CE. Late-onset holocarboxylase synthetase deficiency. *J Inher Metab Dis* 1996;19(6):739–742. [PubMed: 8982946]
66. Suormala T, Fowler B, Duran M, et al. Five patients with a biotin-responsive defect in holocarboxylase formation: evaluation of responsiveness to biotin therapy *in vivo* and comparative biochemical studies *in vitro*. *Pediatrics Res* 1997;41(5):666–673.
67. Suormala T, Fowler B, Jakobs C, et al. Late-onset holocarboxylase synthetase-deficiency: pre- and post-natal diagnosis and evaluation of effectiveness of antenatal biotin therapy. *Eur J Pediatr* 1998;157(7):570–575. [PubMed: 9686819]
68. Wolf B. Worldwide survey of neonatal screening for biotinidase deficiency. *J Inher Metab Dis* 1991;14:923–927. [PubMed: 1779651]
69. Zaffanello M, Zamboni G, Fontana E, Zoccante L, Tato L. A case of partial biotinidase deficiency associated with autism. *Child Neuropsychol* 2003;9(3):184–188. [PubMed: 13680408]
70. Baumgartner ER, Suormala T. Inherited defects of biotin metabolism. *BioFactors (Oxford, England)* 1999;10(2–3):287–290.
71. Wolf B, Grier RE, Allen RJ, Goodman SI, Kien CL. Biotinidase deficiency: an enzymatic defect in late-onset multiple carboxylase deficiency. *Clin Chim Acta* 1983;131:273–281. [PubMed: 6883721]
72. Brenner C. Catalysis in the nitrilase superfamily. *Curr Opin Struct Biol* 2002;12(6):775–782. [PubMed: 12504683]
73. Maras B, Barra D, Dupre S, Pitari G. Is pantetheinase the actual identity of mouse and human vanin-1 proteins. *FEBS Lett* 1999;461:149–152. [PubMed: 10567687]
74. Cole H, Reynolds TR, Lockyer JM, et al. Human serum biotinidase cDNA cloning, sequence, and characterization. *J Biol Chem* 1994;269(9):6566–6570. [PubMed: 7509806]
75. Cole Knight H, Reynolds TR, Meyers GA, et al. Structure of the human biotinidase gene. *Mamm Genome* 1998;9:327–330. [PubMed: 9530634]
76. Stanley CM, Hymes J, Wolf B. Identification of alternatively spliced human biotinidase mRNAs and putative localization of endogenous biotinidase. *Mol Genet Metab* 2004;81(4):300–312. [PubMed: 15059618]
77. Pomponio RJ, Narasimhan V, Reynolds TR, et al. Deletion/insertion mutation that causes biotinidase deficiency may result from the formation of a quasipalindromic structure. *Hum Mol Genet* 1996;5(10):1657–1661. [PubMed: 8894703]
78. Nilsson L, Ronge E. Lipoamidase and biotinidase deficiency: evidence that lipoamidase and biotinidase are the same enzyme in human serum. *Eur J Clin Chem Clin Biochem* 1992;30:119–126. [PubMed: 1599976]
79. Garganta CL, Wolf B. Lipoamidase activity in human serum is due to biotinidase. *Clin Chim Acta* 1990;189(3):313–325. [PubMed: 2225462]
80. Pispa J. Animal biotinidase. *Ann Med Exp Biol Fenniae* 1965;43:4–39.
81. Chew YC, Sarath G, Zempleni J. An avidin-based assay for quantification of histone debiotinylase activity in nuclear extracts from eukaryotic cells. *J Nutr Biochem* 2007;18:475–481. [PubMed: 17156993]
82. Pindolia K, Jensen K, Wolf B. Three dimensional structure of human biotinidase: computer modeling and functional correlations. *Mol Genet Metab* 2007;92(1–2):13–22. [PubMed: 17629531]

83. Swango KL, Wolf B. Conservation of biotinidase in mammals and identification of the putative biotinidase gene in *Drosophila melanogaster*. *Mol Genet Metabol* 2001;74:492–499.
84. Blanton SH, Pandya A, Landa BL, et al. Fine mapping of the human biotinidase gene and haplotype analysis of five common mutations. *Hum Hered* 2000;50(2):102–111. [PubMed: 10799968]
85. Wolf B, Jensen K, Huner G, et al. Seventeen novel mutations that cause profound biotinidase deficiency. *Mol Genet Metab* 2002;77(1–2):108–111. [PubMed: 12359137]
86. Pomponio RJ, Reynolds TR, Cole H, Buck GA, Wolf B. Mutational hotspot in the human biotinidase gene causes profound biotinidase deficiency. *Nat Genet* 1995;11:96–98. [PubMed: 7550325]
87. Wolf B, Feldman GL. The biotin-dependent carboxylase deficiencies. *Am J Hum Genet* 1982;34:699–716. [PubMed: 6127031]
88. Thoene J, Wolf B. Biotinidase deficiency in juvenile multiple carboxylase deficiency. *Lancet* 1983;2(8346):398. [PubMed: 6135890]
89. Muhl A, Moslinger D, Item CB, Stockler-Ipsiroglu S. Molecular characterisation of 34 patients with biotinidase deficiency ascertained by newborn screening and family investigation. *Eur J Hum Genet* 2001;9(4):237–243. [PubMed: 11313766]
90. Wolffe, A. *Chromatin*. Academic Press; CA, USA: 1998.
91. Gorovsky MA. Macro- and micronuclei of *Tetrahymena pyriformis*: a model system for studying the structure of eukaryotic nuclei. *J Protozool* 1973;20:19–25. [PubMed: 4632259]
92. Mathis DJ, Oudet P, Waslyk B, Chambon P. Effect of histone acetylation on structure and *in vitro* transcription of chromatin. *Nucleic Acids Res* 1978;5:3523–3547. [PubMed: 724494]
93. Brownell JE, Zhou J, Ranalli T, et al. *Tetrahymena* histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. *Cell* 1996;84(6):843–851. [PubMed: 8601308]
94. Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to a yeast transcriptional regulator Rpd3. *Science* 1996;272:408–411. [PubMed: 8602529]
95. Jenuwein T, Allis CD. Translating the histone code. *Science* 2001;293:1074–1080. [PubMed: 11498575]
96. Pham A-D, Sauer F. Ubiquitin-activating/conjugating activity of TAF_{II}250, a mediator of activation of gene expression in *Drosophila*. *Science* 2000;289:2357–2360. [PubMed: 11009423]
97. Ausio J, van Holde KE. Histone hyperacetylation: its effect on nucleosome conformation and stability. *Biochemistry* 1986;25:1421–1428. [PubMed: 3964683]
98. Hebbes TR, Thorne AW, Crane-Robinson C. A direct link between core histone acetylation and transcriptionally active chromatin. *EMBO J* 1988;7(5):1395–1402. [PubMed: 3409869]
99. Lee DY, Hayes JJ, Pruss D, Wolffe AP. A positive role for histone acetylation in transcription factor access to nucleosomal DNA. *Cell* 1993;72:73–84. [PubMed: 8422685]
100. Chambon P, Weill JD, Doly J, Stroscher MT, Mandel P. On the formation of a novel adenylic compound by enzymatic extracts of liver nuclei. *Biochem Biophys Res Commun* 1966;25:638–643.
101. Bouliskas T. At least 60 ADP-ribosylated variant histones are present in nuclei from dimethylsulfate-treated and untreated cells. *EMBO J* 1988;7(1):57–67. [PubMed: 3359995]
102. Bouliskas T, Bastin B, Bouliskas P, Dupuis G. Increase in histone poly(ADP-ribosylation) in mitogen-activated lymphoid cells. *Exp Cell Res* 1990;187(1):77–84. [PubMed: 2105227]
103. Fischle W, Wang Y, Allis CD. Histone and chromatin cross-talk. *Curr Opin Cell Biol* 2003;15:172–183. [PubMed: 12648673]
104. Stanley JS, Griffin JB, Zempleni J. Biotinylation of histones in human cells: effects of cell proliferation. *Eur J Biochem* 2001;268:5424–5429. [PubMed: 11606205]
105. Chew YC, Camporeale G, Kothapalli N, Sarath G, Zempleni J. Lysine residues in N- and C-terminal regions of human histone H2A are targets for biotinylation by biotinidase. *J Nutr Biochem* 2006;17(4):225–233. [PubMed: 16109483]
106. Kobza K, Camporeale G, Rueckert B, et al. K4, K9, and K18 in human histone H3 are targets for biotinylation by biotinidase. *FEBS J* 2005;272:4249–4259. [PubMed: 16098205]
107. Kobza K, Sarath G, Zempleni J. Prokaryotic BirA ligase biotinylates K4, K9, K18 and K23 in histone H3. *BMB Reports* 2008;41:310–315. [PubMed: 18452652]

108. Camporeale G, Shubert EE, Sarath G, Cerny R, Zempleni J. K8 and K12 are biotinylated in human histone H4. *Eur J Biochem* 2004;271:2257–2263. [PubMed: 15153116]
109. Bailey LM, Ivanov RA, Wallace JC, Polyak SW. Artifactual detection of biotin on histones by streptavidin. *Anal Biochem* 2008;373(1):71–77. [PubMed: 17920026]
110. Kothapalli N, Sarath G, Zempleni J. Biotinylation of K12 in histone H4 decreases in response to DNA double strand breaks in human JAr choriocarcinoma cells. *J Nutr* 2005;135:2337–2342. [PubMed: 16177192]
111. Camporeale G, Zempleni J, Eissenberg JC. Susceptibility to heat stress and aberrant gene expression patterns in holocarboxylase synthetase-deficient *Drosophila melanogaster* are caused by decreased biotinylation of histones, not of carboxylases. *J Nutr* 2007;137:885–889. [PubMed: 17374649]
112. Camporeale G, Oommen AM, Griffin JB, Sarath G, Zempleni J. K12-biotinylated histone H4 marks heterochromatin in human lymphoblastoma cells. *J Nutr Biochem* 2007;18:760–768. [PubMed: 17434721]
113. Chew YC, West JT, Zempleni J. K12 biotinylated histone H4 is enriched at human endogenous retrovirus promoter regions and may function in retroviral silencing. *FASEB J* 2007;21:855.
114. Gralla M, Camporeale G, Zempleni J. Holocarboxylase synthetase regulates expression of biotin transporters by chromatin remodeling events at the SMVT locus. *J Nutr Biochem* 2008;19:400–408. [PubMed: 17904341]
115. Smith EM, Hoi JT, Eissenberg JC, et al. Feeding *Drosophila* a biotin-deficient diet for multiple generations increases stress resistance and lifespan and alters gene expression and histone biotinylation patterns. *J Nutr* 2007;137:2006–2012. [PubMed: 17709434]
116. Hymes J, Fleischhauer K, Wolf B. Biotinylation of histones by human serum biotinidase: assessment of biotinyl-transferase activity in sera from normal individuals and children with biotinidase deficiency. *Biochem Mol Med* 1995;56(1):76–83. [PubMed: 8593541]
117. Ballard TD, Wolff J, Griffin JB, et al. Biotinidase catalyzes debiotinylation of histones. *Eur J Nutr* 2002;41:78–84. [PubMed: 12083317]

Website

201. National Center for Biotechnology Information. Online Mendelian inheritance in man. [Accessed 21 July 2008]. www.ncbi.nlm.nih.gov/sites/entrez?db=omim

Figure 1. Biotin and its homeostasis

ACC: Acetyl-CoA carboxylase; B: Biotin; BTBD: Biotinidase; HCS: Holo-carboxylase synthetase; MCC: 3-methylcrotonyl-CoA carboxylase; MCT1: Monocarboxylate transporter 1; PC: Pyruvate carboxylase; PCC: Propionyl-CoA carboxylase; SMVT: Sodium-dependent multivitamin transporter.

Figure 2. Modification sites in histones H2A, H3 and H4
 Ac: Acetate; B: Biotin; M: Methyl; P: Phosphate; U: Ubiquitin.